Alterra Medical is a medical device company with experience and proven in catalyzing, capitalizing and commercializing medical devices. They partner with innovators throughout the entire product lifecycle, from ideation and concept feasibility to case validation and national distribution by our clinically-trained sales team.
Xenocor offers a suite of leading edge, fog-free, single-use endoscopes for minimally invasive surgical procedures. This technology emerged from the Center for Medical Innovation at the University of Utah. The current product offerings are FDA cleared, CE Marked and patent protected.
Cross Vascular
Seed Round in 2020
Cross Vascular is a medical device company that develops proprietary cardiovascular technologies. The company was established in 2020 and is based in Solana Beach, CA.
Turner Imaging Systems is a developer of the Smart-C battery-powered mini C-arm. The company develops and markets X-ray imaging systems that give the user the ability to acquire X-ray images wherever and whenever they are needed. The latest product, the SMART-C arm, is a fully-functional mini-C-arm system that is battery operated and hand-transportable, improving the way fluoroscopy is performed. Turner Imaging Systems products expand the reach of X-ray imaging to the under-served and humanitarian efforts around the world.
Layla is the creator of a fertility monitor ring that tracks fertile days. With the company's intravaginal monitoring ring and mobile app, women may determine when cervical fluid is for conception, enabling them to know about their fertile days well in advance and allowing them to take advantage of their whole fertile window.
Healyx Labs is a developer of a wound vacuum system re-engineered to treat wounds across multiple post-acute care settings. The company's Negative Pressure Wound Therapy device delivers continuous, reliable and controlled negative pressure for nearly all Negative Pressure Wound Therapy (NPWT) applications, enabling patients to treat chronic wounds.
Operator of a pharmaceutical company intended to develop new drugs through repositioning. The company focuses on repositioning an already approved and widely used anti-diabetes drug as a medication that slows or stops the progression of calcific aortic valve disease, thus providing the healthcare sector with new technology and medication for a problem that currently has no other remedy.
Alterra Medical is a medical device company with experience and proven in catalyzing, capitalizing and commercializing medical devices. They partner with innovators throughout the entire product lifecycle, from ideation and concept feasibility to case validation and national distribution by our clinically-trained sales team.
iVeena has five products in the late pre-clinical and research phases. Targeted indications include post-surgery cataract inflammation, macular degeneration (Wet AMD), diabetic retinopathy, and glaucoma. iVeena Delivery Systems, Inc. was founded in 2006 by Bala Ambati and is based in Salt Lake City, Utah.
Decoy Biosystems is a biotechnology company developing a novel and potentially best in class, multiple Toll-like receptor (TLR) agonist-based cancer immunotherapy. Decoy is dedicated to enhancing the expanding curative cancer immunology for patients with unresectable or metastatic solid tumors and lymphomas, which are responsible for approximately 90 percent of all cancer deaths.
Navigen, Inc. is a Salt Lake City-based pharmaceutical discovery and development company. Its early strategy was to source early-stage technologies from academia and advance them to IND-enabling studies using non-dilutive funding from grants, contracts, and corporate collaborations. The company has been successfully executed on that strategy, having raised approximately $40 MM in non-dilutive funding and advancing two of its programs to pre-IND studies with the goal of filing IND applications on both within 12-14 months.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.